SF3B1 is an inclusion criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain SF3B1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

SF3B1 is an inclusion criterion in 6 clinical trials for myelodysplastic syndromes, of which 6 are open and 0 are closed. Of the trials that contain SF3B1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

SF3B1 is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain SF3B1 status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain SF3B1 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SF3B1 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].